Local Regulators of Bone: IL-1, TNF, Lymphotoxin, Interferon-γ, the LIF/IL-6 Family, and Additional Cytokines

Principles of Bone Biology: Volume 1-2, Third Edition

Volumn , Issue , 2008, Pages 1209-1234

  Horowitz, Mark C ^a,b   Lorenzo, Joseph A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882467808     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373884-4.00071-9     Document Type: Chapter

References (322)

1. Y. Abu-Amer, S. Abbas and T. Hirayama (2004) TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. J. Cell. Biochem. 93 980-989.
2. T. Akatsu, N. Takahashi, N. Udagawa, K. Imamura, A. Yamaguchi, K. Sato, N. Nagata and T. Suda (1991) Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. Bone Miner. Res. 6 183-190.
3. A. al-Humidan, S.H. Ralston, D.E. Hughes, K. Chapman, L. Aarden, R.G. Russell and M. Gowen (1991) Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J. Bone Miner. Res. 6 3-8.
4. N.N. Ali, V. Gilston and P.G. Winyard (1999) Activation of NF-κB in human osteoblasts by stimulators of bone resorption. FEBS Lett. 460 315-320.
5. M.C. Amaral, S. Miles, G. Kumar and A.E. Nel (1993) Oncostatin-M stimulates tyrosine protein phosphorylation in parallel with the activation of p42MAPK/ERK-2 in Kaposi's cells. J. Clin. Invest. 92 848-857.
6. A. Amcheslavsky and Z. Bar-Shavit (2006) Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides. J. Cell. Physiol. 207 244-250.
7. P. Ammann, I. Garcia, R. Rizzoli, J.-M. Meyer, P. Vassalli and J.-P. Bonjour (1995) Transgenic mice expressing high levels of soluble tumor necrosis factor receptor-1 fusion protein are protected from bone loss by estrogen deficiency. J. Bone Miner. Res. 10 S139. Abstract.
8. W.P. Arend, H.G. Welgus, Thompson and S.P. Eisenberg (1990) Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 85 1694-1697.
9. G.S. Ashcroft, S.J. Mills, K. Lei, L. Gibbons, M-J. Jeong, M. Taniguchi, M. Burow, M.A. Horan, S.M. Wahl and T. Nakayama (2003) Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J. Clin. Invest. 111 1309-1318.
10. S. Avnet, E. Cenni, F. Perut, D. Granchi, M.L. Brandi, A. Giunti and N. Baldini (2007) Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis. Int. J. Oncol. 30 469-476.
11. Y. Azuma, K. Kaji, R. Katogi, S. Takeshita and A. Kudo (2000) Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275 4858-4864.
12. A. Bajayo, I. Goshen, S. Feldman, V. Csernus, K. Iverfeldt, E. Shohami and R. Yirmiya (2005) Central IL-1 receptor signaling regulates bone growth and mass. Proc. Natl. Acad. Sci. USA, 102 12956-12961.
13. J.A. Baugh and R. Bucala (2002) Macrophage migration inhibitory factor. Crit. Care. Med. 30 S27.
14. T. Bellido, R. Jilka, N. Stahl, D. Clark, V. Borba, G. Yancopoulos and S. Manolaga (1994) Phosphorylation of gp130 complexes in stromal/osteoblastic cells following stimulation with IL-6 or LIF: Evidence for distinct responsiveness along the differentiation pathway and perhaps alternate forms of the protein. J. Bone Miner. Res. 9 S150. Abstract
15. T. Bellido, V.Z.C. Borba, N. Stahl, G. Yancopoulos, RL. Jilka and S.C. Manolagas (1995) Ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) stimulate cell proliferation, and increase alkaline phosphatase and interleukin-6 production by osteoblastic cells. J. Bone Miner. Res. 10 S319. Abstract
16. T. Bellido, V.Z.C. Borba, P. Roberson and S.C. Manolagas (1997) Activation of the Janus Kinase/STAT (Signal Transducer and Activator of Transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 138 3666-3676.
17. A.C. Bendixen, N.K. Shevde, K.M. Dienger, T.M. Willson, C.D. Funk and J.W. Pike (2001) IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc. Natl. Acad. Sci. USA, 98 2443-2448.
18. D. Bertolini, G. Nedwin, T. Bringman, D. Smith and G. Mundy (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 319 516-518.
19. E. Bettelli, Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, H.L. Weiner and V.K. Kuchroo (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 235-238.
20. B. Beutler and A. Cerami (1986) Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 320 584-588.
21. H. Bismar, I. Diel, R. Ziegler and J. Pfeilschifter (1995) Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J. Clin. Endocrinol. Metab. 80 3351-3355.
22. G. Bollag and R. McCormick (1991) Regulators and effectors of ras proteins. Annu. Rev. Cell Biol. 7 601-632.
23. A. Bonni, D.A. Frank, C. Schindler and M.E. Greenberg (1993) Characterization of a pathway for ciliary neurotrophic factor signaling to the nucleus. Science 262 1575-1579.
24. B.F. Boyce, T.B. Aufdemorte, R. Garrett, A.J.P. Yates and G.R. Mundy (1989) Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 125 1142-1150.
25. D. Burger, R. Chicheportiche, J.G. Giri and J. Dayer (1995) The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type 1 interleukin-1 soluble receptor. J. Clin. Invest. 96 38-41.
26. E. Canalis (1986) Interleukin-1 has independent effects on deoxyribonucleic acid and collagen synthesis in cultures of rat calvariae. Endocrinology 118 74-81.
27. E. Canalis (1987) Effects of tumor necrosis factor on bone formation in vitro. Endocrinology 121 1596-1604.
28. E.E. Carmody, E.M. Schwarz, J.E. Puzas, R.N. Rosier and R.J. O'Keefe (2002) Viral interleukin-10 gene inhibition of inflammation, osteoclastogenesis, and bone resorption in response to titanium particles. Arthritis Rheum. 46 1298-1308.
29. A. Carter, S. Merchav, I. Silvian Draxler and I. Tatarsky (1990) The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br. J. Haematol. 74 424-431.
30. S. Cenci, M.N. Weitzmann, C. Roggia, N. Namba, D. Novack, J. Woodring and R. Pacifici (2000) Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J. Clin. Invest. 106 1229-1237.
31. M. Centrella, T.L. McCarthy and E. Canalis (1988) Tumor necrosis factor-alpha inhibits collagen synthesis and alkaline phosphatase activity independently of its effect on deoxyribonucleic acid synthesis in osteoblast-enriched bone cell cultures. Endocrinology 123 1442-1448.
32. N. Charatcharoenwitthaya, S. Khosla, E.J. Atkinson, L.K. McCready and B.L. Riggs (2007) Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J. Bone Miner. Res. 22 724-729.
33. L.R. Chaudhary and L.V. Avioli (1995) Dexamethasone regulates IL-1-β and TNF-α-induced interleukin-8 production in human bone marrow stromal and osteoblast-like cells. Calcif. Tissue Int. 55 16-20.
34. L.R. Chaudhary, T.C. Spelsberg and B.L. Riggs (1992) Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1β and tumor necrosis factor-α: Lack of regulation by 17β3-estradiol. Endocrinology 130 2528-2534.
35. C. Chipoy, M. Berreur, S. Couillaud, G. Pradal, F. Vallette, C. Colombeix, F. Redini, D. Heymann and F. Blanchard (2004) Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKC and STAT3. J. Bone Miner. Res. 19 1850-1861.
36. S.J. Choi, J.C. Cruz, F. Craig, H. Chung, R.D. Devlin, G.D. Roodman and M. Alsina (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96 671-675.
37. M.E. Cohen-Solal, A.M. Graulet, M.A. Denne, J. Gueris, D. Baylink and M.C. De Vernejoul (1993) Peripheral monocyte culture supernatants of menopausal women can induce bone resorption: Involvement of cytokines. J. Clin. Endocrinol. Metab. 77 1648-1653.
38. F. Colotta, F. Re, M. Muzio, R. Bertini, N. Polentarutti, M. Sironi, J.G. Giri, S.K. Dower, J.E. Sims and A. Mantovani (1993) Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 261 472-475.
39. V. Cormier-Daire, A. Superti-Furga, A. Munnich, S. Lyonnet, P. Rustin, A.L. Delezoide, P. De Lonlay, A. Giedion, P. Maroteaux and M. Le Merrer (1998) Clinical homogeneity of the Stuve-Wiedemann syndrome and overlap with the Schwartz-Jampel syndrome type 2. Am. J. Med. Genet. 78 146-149.
40. J. Cornish, M.T. Gillespie, K.E. Callon, N.J. Horwood, J.M. Moseley and I.R. Reid (2003) Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology 144 1194-1201.
41. N. Dagoneau, D. Scheffer, C. Huber, LI. Al-Gazali, M. Di Rocco, A. Godard, J. Martinovic, A. Raas-Rothschild, S. Sigaudy, S. Unger, S. Nicole, B. Fontaine, J.L. Taupin, J.F. Moreau, A. Superti-Furga, M. Le Merrer, J. Bonaventure, A. Munnich, L. Legeai-Mallet and V. Cormier-Daire (2004) Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. Am. J. Hum. Genet. 74 298-305.
42. S.M. Dai, K. Nishioka and K. Yudoh (2004) Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. Ann. Rheum. Dis. 63 1379-1386.
43. P.D. Damoulis and P.V. Hauschka (1997) Nitric oxide acts in conjunction with proinflammatory cytokines to promote cell death in osteoblasts. J. Bone Miner. Res. 12 412-422.
44. J. Darnell Jr., I. Kerr and G. Stark (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 1415-1421.
45. S. Davis, T.H. Aldrich, D.M. Valenzuela, V. Wong, M.E. Furth, S.P. Squinto and G.D. Yancopoulos (1991) The receptor for ciliary neurotrophic factor. Science 253 59-63.
46. D. Derouet, F. Rousseau, F. Alfonsi, J. Froger, J. Hermann, F. Barbier, D. Perret, C. Diveu Ca., C. Guillet Ca., L. Preisser, A. Dumont, M. Barbado, A. Morel, O. deLapeyriere, H. Gascan and S. Chevalier (2004) Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. Proc. Natl. Acad. Sci. USA, 101 4827-4832.
47. F.E. Dewhirst, P.P. Stashenko, M.J. E. and T. Tsurumachi (1985) Purification and partial sequence of human osteoclast-activating factor: Identity with interleukin 1 beta. J. Immunol. 135 2562-2568.
48. C.A. Dinarello (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77 1627-1652.
49. C.A. Dinarello (1993) Blocking interleukin-1 in disease. Blood Purif. 11 118-127.
50. C.A. Dinarello (1993) Modalities for reducing interleukin 1 activity in disease. Trends Pharmacol. Sci. 14 155-159.
51. J.A. Elias, W. Tang and M.C. Horowitz (1995) Cytokine and hormonal stimulation of human osteoblasts interleukin-11 production. Endocrinology 136 489-498.
52. T.A. Endo, M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, K. Mitsui, A. Matsumoto, S. Tanimura, M. Ohtsubo, H. Misawa, T. Miyazaki, N. Leonor, T. Taniguchi, T. Fujita, Y. Kanakura, S. Komiya and A. Yoshimura (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387 921-924.
53. S.L. Erickson, S.F. de, K. Kikly, K. Carver-Moore, S. Pitts-Meek, N. Gillett, K.C. Sheehan, R.D. Schreiber, D.V. Goeddel and M.W. Moore (1994) Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372 560-563.
54. K.E. Evans and SW. Fox (2007) Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol. 19 8:4.
55. D. Falconi, K. Oizumi and J.E. Aubin (2007) Leukemia inhibitory factor influences the fate choice of mesenchymal progenitor cells. Stem Cells 25 305-312.
56. W. Fiers (1993) Tumor necrosis factor. E. Sim (Eds) The Natural Immune System: Humoral Factors Oxford: IRL Press at Oxford University Press 65-119.
57. C.E. Fiore, E. Falcidia, R. Foti, M. Motta and C. Tamburino (1994) Differences in the time course of the effects of oophorectomy in women on parameters of bone metabolism and interleukin-1 levels in the circulation. Bone Miner. 20 79-85.
58. I. Firmbach-Kraft, M. Byers, T. Shows, R. Dalla-Favera and J.J. Krolewski (1990) Tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 5 1329-1336.
59. M.M. Fort, J. Cheung, D. Yen, J. Li, S.M. Zurawski, S. Lu, S. Menon, T. Clifford, B. Hunte, R. Lesley, T. Muchamuel, S.D. Hurst, G. Zurawski, M.W. Leach, D.M. Gorman and D.M. Rennick (2001) IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15 985-995.
60. S.W. Fox and T.J. Chambers (2000) Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. Biochem. Biophys. Res. Commun. 276 868-872.
61. K. Fuller, J.M. Owens and T.J. Chambers (1995) Macrophage inflammatory protein-1α and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts. J. Immunol. 154 6065-6072.
62. Y. Gao, F. Grassi, M.R. Ryan, M. Terauchi, K. Page, X. Yang, MN. Weitzmann and R. Pacifici (2007) IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J. Clin. Invest. 117 122-132.
63. I.R. Garrett, B.G.M. Durie, G.E. Nedwin, A. Gillespie, T. Bringman, M. Sabatini, D.R. Bertolini and G.R. Mundy (1987) Production of Lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N. Engl. J. Med. 317 526-532.
64. D.P. Gearing (1993) The leukemia inhibitory factor and its receptor. Adv. Immunol. 53 31-58.
65. D.P. Gearing and A.G. Bruce (1992) Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. New Biol. 4 61-65.
66. D.P. Gearing, M.R. Corneau, D.J. Friend, S.D. Gimpel, C.J. Thut, J. McGourty, K.K. Brasher, J.A. King, S. Gillis, B. Mosley, S.F. Ziegler and D. Cosman (1992) The IL-6 signal transducer, gp130: An Oncostatin M receptor and affinity converter for the LIF receptor. Science 255 1434-1437.
67. L. Gilbert, X. He, P. Farmer, S. Boden, M. Kozlowski, J. Rubin and M.S. Nanes (2000) Inhibition of osteoblast differentiation by tumor necrosis factor-α. Endocrinology 141 3956-3964.
68. L.C. Gilbert, J. Rubin and M.S. Nanes (2005) The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am. J. Physiol. 288 E1011-eE1018.
69. G. Girasole, R.L. Jilka, G. Passeri, S. Boswell, G. Boder, D.C. Williams and S.C. Manolagas (1992) 17 Beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89 883-891.
70. G. Girasole, G. Passeri, R.L. Jilka and S.C. Manolagas (1994) Interleukin-11: A new cytokine critical for osteoclast development. J. Clin. Invest. 93 1516-1524.
71. G.R. Goodman, I.R. Dissanayake, E. Gorodetsky, H. Zhou, Y.F. Ma, W.S. Jee and S. Epstein (1999) Interferon-alpha, unlike interferon-gamma, does not cause bone loss in the rat. Bone 25 459-463.
72. M. Gowen, K. Chapman, A. Littlewood, D. Hughes, D. Evans and R.G.G. Russell (1990) Production of tumor necrosis factor by human osteoblasts is modulated by other cytokines, but not by osteotropic hormones. Endocrinology 126 1250-1255.
73. M. Gowen, B.R. MacDonald and G.G. Russell (1988) Actions of recombinant human gamma-interferon and tumor necrosis factor alpha on the proliferation and osteoblastic characteristics of human trabecular bone cells in vitro. Arthritis Rheum. 31 1500-1507.
74. M. Gowen and G.R. Mundy (1986) Actions of recombinant interleukin-1, interleukin-2 and interferon gamma on bone resorption in vitro. J. Immunol. 136 2478-2482.
75. M. Gowen, G.E. Nedwin and G.R. Mundy (1986) Preferential inhibition of cytokine-stimulated bone resorption by recombinant interferon gamma. J. Bone Miner. Res. 1 469-474.
76. M. Gowen, D.D. Wood, E.F. Ihrie, M.K.B. McGuire and R.G.G. Russell (1983) An interleukin 1-like factor stimulates bone resorption in vitro. Nature 306 378-380.
77. M. Gowen, D.D. Wood and R.G.G. Russell (1985) Stimulation of the proliferation of human bone cells in vitro by human monocyte products with interleukin-1 activity. J. Clin. Invest. 75 1223-1229.
78. D.T. Graves, Y. Jiang and A.J. Valente (1999) Regulated expression of MCP-1 by osteoblastic cells in vitro and in vivo. Histol. Histopathol. 14 1347-1354.
79. E.M. Greenfield, S.A. Gronik, M.C. Horowitz, H.J. Donahue and S.M. Shaw (1993) Regulation of cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J. Bone Miner. Res. 8 1163-1171.
80. A. Grey, M. Mitnick, U. Masiukiewicz, B-H. Sum, S. Rudikoff, R. Jilka, S. Manolagas and K. Insogna (1999) A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 140 4683-4690.
81. P.H. Hart, G.F. Vitti, D.R. Burgess, G.A. Whitty, D.S. Piccoli and J.A. Hamilton (1989) Potential anti-inflammatory effects of interleukin 4: Suppression of human monocytes tumor necrosis factor a, interleukin 1, and prostaglandin E2. Proc. Natl. Acad. Sci. USA, 86 3803-3807.
82. G. Hattersley, E. Dorey, M.A. Horton and T.J. Chambers (1988) Human macrophage colony-stimulating factor inhibits bone resorption by osteoblasts disaggregated from rat bone. J. Cell. Physiol. 137 199-203.
83. S. Hayer, G. Steiner, B. Gortz, E. Reiter, M. Tohidast-Akrad, M. Amling, O. Hoffmann, K. Redlich, J. Zwerina, K. Shriner, F. Hilberg, E.F. Wagner, J.S. Smolen and G. Schett (2005) CD44 is a determinant of inflammatory bone loss. J. Exp. Med. 201 903-914.
84. D.R. Haynes, G.J. Atkins, M. Loric, T.N. Crotti, S.M. Geary and D.M. Findlay (1999) Bidirectional signaling between stromal and hemopoietic cells regulates interleukin-1 expression during human osteoclast formation. Bone 25 269-278.
85. P.C. Heinrich, I. Behrmann, S. Haan, H.M. Hermanns, G. Muller-Newen and F. Schaper (2003) Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem J. 374 1-20.
86. H.M. Hermanns, S. Radtke, F. Schaper, P.C. Heinrich and I. Behrmann (2000) Non-redundant signal transduction of interleukin-6-type cytokines. The adapter protein she is specifically recruited to rhe oncostatin M receptor. J. Biol Chem. 275 40742-40748.
87. H. Hikiji, W.S. Shin, S. Oida, T. Takato, T. Koizumi and T. Toyo-Oka (1997) Direct action of nitric oxide on osteoblastic differentiation. FEBS Lett. 410 238-242.
88. H. Hikiji, W.S. Shin, T. Koizumi, T. Takato, T. Susami, Y. Koizumi, Y. Okai-Matsuo and T. Toyo-Oka (2000) Peroxynitrite production by TNF-α and IL-1β: Implication for suppression of osteoblastic differentiation. Am. J. Physiol. 278 E1031-eeE1037.
89. D. Hilton, A. Hilton, A. Raicevic, S. Rakar, M. Harrison-Smith, N. Gough, C. Begley, D. Metcalf, N. Nicola and T. Wilson (1994) Cloning of a murine IL-11 receptor α-chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J. 13 4765-4775.
90. L.C. Hofbauer, C.R. Dunstan, T.C. Spelsberg, B.L. Riggs and S. Khosla (1998) Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem. Biophys. Res. Commun. 250 776-781.
91. L.C. Hofbauer, D.L. Lacey, C.R. Dunstan, T.C. Spelsberg, B.L. Riggs and S. Khosla (1999) Interleukin-1beta and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25 255-259.
92. L.C. Hofbauer, C. Shui, B.L. Riggs, C.R. Dunstan, T.C. Spelsberg, T. O'Brien and S. Khosla (2001) Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem. Biophys. Res Commun. 280 334-339.
93. C.A. Holding, D.M. Findlay, R. Stamenkov, S.D. Neale, H. Lucas, A.S. Dharmapatni, S.A. Callary, K.R. Shrestha, G.J. Atkins, D.W. Howie and D.R. Haynes (2006) The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 27 5212-5219.
94. M.H. Hong, H. Williams, C.H. Jin and J.W. Pike (2000) The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins. J. Bone Miner. Res. 15 911-918.
95. M.C. Horowitz and J.B. Levy (1995) Differential usage of adaptor proteins in the activation of the Ras pathway by oncostatin M in osteoblasts. J. Bone Miner. Res. 10 S309. Abstract
96. M.C. Horowitz, W.M. Philbrick and R.L. Jilka (1989) IL-1 release from cultured calvarial cells is due to macrophages. J. Bone Miner. Res. 4 556. Abstract
97. M.C. Horowitz, N. Stahl, A. Fields, A. Baron and J.B. Levy (1994) Differential signal transduction induced by LIF/IL-6 type cytokines in osteoblasts. J. Bone Miner. Res. 9 S170. Abstract
98. M. Horowitz, M. Brown, K. Insogna, D. Coleman, M. Centrella, J. Phillips and E. Weir (1990) PTHrP and PTH induce the secretion of IL-6 by a clonal osteosarcoma cell line. J.J. Oppenheim, M.C. Powanda, M.J. Kluger, C.A. Dinarello (Eds) Molecular and Cellular Biology of Cytokines New York: Wiley-Liss 471-476.
99. M.C. Horowitz, D.V. Distasio, B. Mosley and J.B. Levy (1996) Identification of the Oncostatin M specific receptor on human osteoblasts. J. Bone Miner. Res. 11, S141 Abstract
100. R. Horuk (1994) Molecular properties of the chemokine receptor family. Trends Pharmacol. Sci. 15 159-165.
101. N.J. Horwood, J. Elliott, T.J. Martin and M.T. Gillespie (2001) IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. 166 4915-4921.
102. N.J. Horwood, N. Udagawa, J. Elliott, D. Grail, H. Okamura, M. Kurimoto, A.R. Dunn, T. Martin and M.T. Gillespie (1998) Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J. Clin. Invest. 101 595-603.
103. M. Howard, F. John, M. Hilfiker, B. Johnson, K. Takatsu, T. Kamaoka and W.E. Paul (1982) Identification of a T cell derived B cell growth factor distinct from interleukin 2. J. Exp. Med. 155 914-923.
104. C.S. Hsieh, S.E. Macatonia, C.S. Tripp, S.F. Wolf, A. O'Garra and K.M. Murphy (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260 547549.
105. F.G. Hustmeyer, E. Walker, X.P. Xu, G. Girasole, Y. Sakagami, M. Peacock and S.C. Manolagas (1993) Cytokine production and surface antigen expression by peripheral blood mononuclear cells in post-menopausal osteoporosis. J. Bone Miner. Res. 8 1135-1141.
106. R.L. Idzerda, C.J. March, B. Mosley, S.D. Lyman, BT. Vanden, S.D. Gimpel, W.S. Din, K.H. Grabstein, M.B. Widmer, L.S. Park, D. Cosman and M.P. Beckmann (1990) Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J. Exp. Med. 171 861-873.
107. N.Y. Ip, S.H. Nye, T.G. Boulton, S. Davis, T. Taga, Y. Li, S.J. Birren, K. Yasukawa, T. Kishimoto, D.J. Anderson, N. Stahl and G.D. Yancopoulos (1992) CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell 69 1121-1132.
108. J. Iqbal, L. Sun, T.R. Kumar, H.C. Blair and M. Zaidi (2006) Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc. Natl. Acad. Sci. USA, 103 14925-14930.
109. Y. Ishimi, C. Miyaura, C. He Jin, T. Akatsu, E. Abe, Y. Nakamura, A. Yamaguchi, S. Yoshiki, T. Matsuda, T. Hirano, T. Kishimoto and T. Suda (1990) IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 10 3297-3303.
110. J.O. Jansson, S. Movérare-Skrtic, A. Berndtsson, I. Wernstedt, H. Caristen and C. Ohisson (2006) Leukemia inhibitory factor reduces body fat mass in ovariectomized mice. Eur. J. Endocrinol. 154 349-354.
111. P. Jay, M. Centrella, J. Lorenzo, A.G. Bruce and MC. Horowitz (1996) Oncostatin M: A new cytokine which activates osteoblast and inhibits bone resorption. Endocrinology 137 1151-1158.
112. R.L. Jilka, G. Hangoc, G. Girasole, G. Passeri, D.C. Williams, J.S. Abrams, B. Boyce, H. Broxmeyer and S.C. Manolagas (1992) Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257 88-91.
113. R.L. Jilka, R.S. Weinstein, T. Bellido, A.M. Parfitt and S.C. Manolagas (1998) Osteoblast programmed cell death (apoptosis): Modulation by growth factors and cytokines. J. Bone Miner. Res. 13 793-802.
114. E. Jimi, T. Ikebe, N. Takahashi, M. Hirata, T. Suda and T. Koga (1996) Interleukin-1α activates all NF-κB-like factor in osteoclast-like cells. J. Biol. Chem. 271 4605-4608.
115. E. Jimi, S. Akiyama, T. Tsurukai, N. Okahashi, K. Kobayashi, N. Udagawa, T. Nishihara, N. Takahashi and T. Suda (1999) Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163 434-442.
116. R.A. Johnson, B.F. Boyce, G.R. Mundy and G.D. Roodman (1989) Tumors producing human tumor necrosis factor induce hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology 124 1424-1427.
117. R.A. Kastelein, C.A. Hunter and D.J. Cua (2007) Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25 221-242.
118. W.M. Kavanaugh and L.T. Williams (1995) An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science 266 1862-1865.
119. H. Kawaguchi, C.C. Pilbeam, S.J. Vargas, E.E. Morse, J.A. Lorenzo and L.G. Raisz (1995) Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvaria. J. Clin. Invest. 96 539-548.
120. H. Kawaguchi, K. Nemoto, L.G. Raisz, J.R. Harrison, O.S. Voznesensky, C.B. Alander and C. Pilbeam (1996) Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures. J. Bone Miner. Res. 11 358-366.
121. Y. Kawase, T. Hoshino, K. Yokota, A. Kuzuhara, M. Nakamura, Y. Maeda, E. Nishiwaki, M. Zenmyo, K. Hiraoka, H. Aizawa and K. Yoshino (2003) Bone malformations in interleukin-18 transgenic mice. J. Bone Miner. Res. 18 975-983.
122. P.E. Keeting, L. Rifas, S.A. Harris, D.S. Colvard, T.C. Spelsberg, W.A. Peck and B.L. Riggs (1991) Evidence for interleukin-1 beta production by cultured normal human osteoblast-like cells. J. Bone Miner. Res. 6 827-833.
123. L.L. Key Jr., W.L. Ries, R.M. Rodriguiz and H.C. Hatcher (1992) Recombinant human interferon gamma therapy for osteopetrosis. J. Pediatr. 121 119-124.
124. L.L. Key Jr., R.M. Rodriguiz, S.M. Willi, N.M. Wright, H.C. Hatcher, D.R. Eyre, J.K. Cure, P.P. Griffin and W.L. Ries (1995) Long-term treatment of osteopetrosis with recombinant human interferon gamma. N. Engl. J. Med. 332 1594-1599.
125. S. Khosla, J.M. Peterson, K. Egan, J.D. Jones and BL. Riggs (1994) Circulating cytokine levels in osteoporotic and normal women. J. Clin. Endocrinol. Metab. 79 707-711.
126. J.G. Kim, K.S. Lim, S.Y. Ku, S.H. Kim, Y.M. Choi and S.Y. Moon (2006) Relations between interleukin-1, its receptor antagonist gene polymorphism, and bone mineral density in postmenopausal Korean women. J. Bone Miner. Metab. 24 53-57.
127. N. Kim, Y. Kadono, M. Takami, J. Le, S.H. Lee, F. Okada, J.M. Kim, T. Kobayashi, P.R. Odgren, H. Nakano, W.C. Yeh, S.K. Lee, J.A. Lorenzo and Y. Choi (2005) Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J. Exp. Med. 202 589-595.
128. R.B. Kimble, J.L. Vannice, D.C. Bloedow, R.C. Thompson, W. Hopfer, V.T. Kung, C. Brownfield and R. Pacifici (1994) Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J. Clin. Invest. 93 1959-1967.
129. R.B. Kimble, S.D. Bain, V. Kung and R. Pacifici (1995) Inhibition of IL-6 activity in genetically normal mice does not prevent ovariectomy-induced bone loss. J. Bone Miner. Res. 10 S160. Abstract
130. R.B. Kimble, A.B. Matayoshi, J.L. Vannice, V.T. Kung, C. Williams and R. Pacifici (1995) Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 136 3054-3061.
131. H. Kitaura, P. Zhou, H.J. Kim, D.V. Novack, F.P. Ross and S.L. Teitelbaum (2005) M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Invest. 115 3418-3427.
132. R. Kitazawa, R.B. Kimble, J.L. Vannice, V.T. Kung and R. Pacifici (1994) Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 94 2397-2406.
133. D.C. Klein and L.G. Raisz (1970) Prostaglandins: Stimulation of bone resorption in tissue culture. Endocrinology 86 1436-1440.
134. S. Knudsen, T. Harslof, L.B. Husted, M. Carsten, L. Stenkjaer and B.L. Langdahl (2007) The effect of interleukin-1alpha polymorphisms on bone mineral density and the risk of vertebral fractures. Calcif. Tissue Int. 80 21-30.
135. K. Kobayashi, N. Takahashi, E. Jimi, N. Udagawa, M. Takami, S. Kotake, N. Nakagawa, M. Kinosaki, K. Yamaguchi, N. Shima, H. Yasuda, T. Morinaga, K. Higashio, T.J. Martin and T. Suda (2000) Tumor Necrosis Factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191 275-286.
136. M.I. Koenders, E. Lubberts, B. Oppers-Walgreen, L. van den Bersselaar, M.M. Helsen, F.E. Di Padova, A.M. Boots, H. Gram, L.A. Joosten and W.B. van den Berg (2005) Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am. J. Pathol. 167 141-149.
137. R. Kolesnick and D.W. Golde (1994) The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77 325-328.
138. S. Kotake, N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, K. Inoue, N. Kamatani, M.T. Gillespie, T.J. Martin and T. Suda (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103 1345-1352.
139. G. Kumar, S. Gupta, S. Wang and A. Nel (1994) Involvement of Janus kinases, p52shc, Raf-1, and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B cell line. J. Immunol. 153 4436-4447.
140. H.B. Kwak, H.M. Jin, H. Ha, M.J. Kang, S.B. Lee, H.H. Kim and Z.H. Lee (2005) Tumor necrosis factor-alpha induces differentiation of human peripheral blood mononuclear cells into osteoclasts through the induction of p21(WAF1/Cip1). Biochem Biophys. Res. Commun. 330 1080-1086.
141. D.L. Lacey, J.M. Erdmann, M. Shima, M. Kling, A. Matayoshi, M. Gorospe, C. Cirielli, X. Wang, P. Seth, M.C. Capogrossi and N.J. Holbrook (1997) p21Waf1/Cipl protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14 929-935.
142. D.L. Lacey, J.M. Erdmann, H.-L. Tan and J. Ohara (1993) Murine osteoblast interleukin 4 receptor expression: Upregulation by 1, 25-Dihydroxyvitamin D3. J. Cell. Biochem. 53 122-134.
143. D.L. Lacey, J.M. Erdmann, M. Shima, M. Kling, A. Matayoshi, J. Ohara and S.L. Perkins (1994) Interleukin 4, enhances osteoblast macrophage colony-stimulating factor, but not interleukin 6, production. Calcif. Tissue Int. 55 21-28.
144. D.L. Lacey, J.M. Erdmann, S.L. Teitelbaum, H.-L. Tan, J. Ohara and A. Shioi (1995) Interleukin 4, interferon-γ and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages. Endocrinology 236 2367-2376.
145. J. Lam, S. Takeshita, J.E. Barker, O. Kanagawa, F.P. Ross and S.L. Teitelbaum (2000) TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106 1481-1488.
146. C. Lambert, C. Oury, E. Dejardin, A. Chariot, J. Piette, M. Malaise, M.P. Merville and N. Franchimont (2007) Further insights in the mechanisms of interleukin-1beta stimulation of osteoprotegerin in osteoblast-like cells. J. Bone Miner. Res. 22 1350-1361.
147. B.L. Langdahl, E. Lokke, M. Carstens, L.L. Stenkyaer and E.F. Erickson (2000) Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1-receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. J. Bone Miner. Res. 15 402-414.
148. M.J. Layton, B.A. Cross, D. Metcalf, L.D. Ward, RJ. Simpson and N.A. Nicola (1992) A major binding protein for leukemia inhibitory factor in normal mouse serum: Identification as a soluble form of the cellular receptor. Proc. Natl. Acad. Sci. USA, 89 8616-8620.
149. S. Lee, C. Jacquin, L. Leng, R. Bucala and G. Kuchel (2006) Macrophage migration inhibitory factor is an inhibitor of osteoclastogenesis in vitro and in vivo. J. Bone Miner. Res. 21 SA246. Abstract
150. S.K. Lee, Y. Kadono, F. Okada, D. Jacquin, B. Koczon-Jaremko, G. Gronowicz, D.J. Adams, H.L. Aquila, Y. Choi and J.A. Lorenzo (2006) T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J. Bone Miner. Res. 21 1704-1712.
151. S.K. Lee, J.F. Kalinowski, S.L. Jastrzebski, L. Puddington and J.A. Lorenzo (2003) Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Endocrinology 144 3524-3531.
152. S.K. Lee, J.F. Kalinowski, C. Jacquin, D.J. Adams, G. Gronowicz and J.A. Lorenzo (2006) Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J. Bone Miner. Res. 21 695-702.
153. Z.H. Lee, S.E. Lee, C.W. Kim, S.H. Lee, S.W. Kim, K. Kwack, K. Walsh and H.H. Kim (2002) IL-1alpha stimulation of osteoclast survival through the PI 3-kinase/Akt and ERK pathways. J. Biochem. (Tokyo), 131 161-166.
154. J.B. Levy, C. Schindler, R. Rax, D.E. Levy, R. Baron and M.C. Horowitz (1996) Activation of the JAK-STAT signal transduction path-way by oncostatin-M in cultured human and mouse osteoblasts. Endocrinology 137 1159-1165.
155. D.B. Lewis, H.D. Liggitt, E.L. Effmann, S.T. Motley, S.L. Teitelbaum, K.L. Jepsen, S.A. Goldstein, J. Bonadio, J. Carpenter and R.M. Perlmutter (1993) Osteoporosis induced in mice by overexpression of interleukin 4. Proc. Natl. Acad. Sci. USA, 90 11618-11622.
156. H. Li, E. Cuartas, W. Cui, Y. Choi, T.D. Crawford, H.Z. Ke, K.S. Kobayashi, R.A. Flavell and A. Vignery (2005) IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation. J. Exp. Med. 201 1169-1177.
157. J. Li, I. Sarosi, X.Q. Yan, S. Morony, C. Capparelli, H.L. Tan, S. McCabe, R. Elliott, S. Scully, G. Van, S. Kaufman, S.C. Juan, Y. Sun, J. Tarpley, L. Martin, K. Christensen, J. McCabe, P. Kostenuik, H. Hsu, F. Fletcher, C.R. Dunstan, D.L. Lacey and W.J. Boyle (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA, 97 1566-1571.
158. P. Li, E.M. Schwarz, R.J. O'Keefe, L. Ma, F.F. Boyce and L. Xing (2004) RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J. Bone Miner. Res. 19 207-213.
159. P. Li, E.M. Schwarz, R.J. O'Keefe, L. Ma, R.J. Looney, C.T. Ritchlin, F. boyce F.f. and L. Xing (2004) Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum. 50 265-276.
160. J.A. Lorenzo (1991) The role of cytokines in the regulation of local bone resorption. Crit. Rev. Immunol. 11 195-213.
161. J.A. Lorenzo, S.L. Sousa, C. Alander, L.G. Raisz and C.A. Dinarello (1987) Comparison of the bone-resorbing activity in the supernatants from phytohemagglutinin-stimulated human peripheral blood mononuclear cells with that of cytokines through the use of an antiserum to interleukin 1. Endocrinology 121 1164-1170.
162. J.A. Lorenzo, S.L. Sousa and C.L. Leahy (1990) Leukemia inhibitory factor (LIF) inhibits basal bone resorption in fetal rat long bone cultures. Cytokine 2 266-271.
163. J.A. Lorenzo, S.L. Sousa, S.E. Van Den Brink-Webb and J.H. Korn (1990) Production of both interleukin-1α and β by newborn mouse calvaria cultures. J. Bone Miner. Res. 5 77-83.
164. C. Lowe, G.A.J. Gillespie and J.W. Pike (1995) Leukemia inhibitory factor as a mediator of JAK/STAT activation in murine osteoblasts. J. Bone Miner. Res. 10 1644-1650.
165. E. Lubberts, L.A.B. Joosten, M. Chabaud, L. Van den Bersselaar, B. Oppers, C.J.J. Coenen-de Roo, C.D. Richards, P. Miossec and W.B. Van den Berg (2000) IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J. Clin. Invest. 105 1697-1710.
166. E. Lubberts, B.L. Van Den, B. Oppers-Walgreen, P. Schwarzenberger, C.J. Coenen-de Roo, J.K. Kolls, L.A. Joosten and W.B. van den Berg (2003) IL-17 Promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappaB ligand/osteoprotegerin balance. J. Immunol. 170 2655-2662.
167. T. Ma, K. Miyanishi, A. Suen, N.J. Epstein, T. Tomita, R.L. Smith and S.B. Goodman (2004) Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-alpha. Cytokine 26 138-144.
168. Y.L. Ma, Q.O. Zeng, R.L. Cain, X.Y. Tian, R. Zhao, W.S.S. Jee, W. Zend, J. Salfity, M. Sato, H.U. Bryant and L. Liu (2006) Bone anabolic effects of recombinant human IL-11 (rhIL-11) are comparable to PTH in osteopenic ovariectomized mice. J. Bone Miner. Res. M392 S427. Abstract
169. H. MacPherson, B.S. Noble and S.H. Ralston (1999) Expression and functional role of nitric oxide synthase isoforms in human osteoblast-like cells. Bone 24 179-185.
170. C. Makiishi-Shimobayashi, T. Tsujimura, T. Iwasaki, N. Yamada, A. Sugihara, H. Okamura, S. Hayashi and N. Terada (2001) Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem. Biophys. Res. Commun. 281 361-366.
171. L. Malaval, A.K. Gupta and J.E. Aubin (1995) Leukemia inhibitory factor inhibits osteogenic differentiation in rat calvarial cell cultures. Endocrinology 136 1411-1418.
172. L. Malaval, A.K. Gupta, F. Liu, P.D. Delmas and J.E. Aubin (1998) LIF, but not IL-6, regulates osteoprogenitor differentiation in rat calvaria cell cultures: Modulation by dexamethasone. J. Bone Miner. Res. 13 175-184.
173. L. Malaval, F. Liu, A.B. Vernallis and J.E. Aubin (2005) GP130/OSMR is the only LIF. IL6 family receptor complex to promote osteoblast differentiation of calvaria progenitors. J. Cell. Physiol. 204 585-593.
174. N. Malik, H.S. Haugen, B. Modrell, M. Shoyab and C.H. Clegg (1995) Developmental abnormalities in mice transgenic for bovine oncostatin M. Mol. Cell. Biol. 15 2349-2358.
175. S.W. Mamus, S. Beck-Schroeder and E.D. Zanjani (1985) Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes. J. Clin. Invest. 75 1496-1503.
176. G.N. Mann, T.W. Jacobs, F.J. Buchinsky, E.C. Armstrong, M. Li, H.Z. Ke, Y.F. Ma, W.S.S. Jee and S. Epstein (1994) Interferon-gamma causes loss of bone volume in vivo and fails to ame-liorate cyclosporin A-induced osteopenia. Endocrinology 135 1077-1083.
177. A. Marusic, J.F. Kalinowski, S. Jastrzebski and J.A. Lorenzo (1993) Production of leukemia inhibitory factor mRNA and protein by malignant and immortalized bone cells. J. Bone Miner. Res. 8 617-624.
178. W.R. McKane, S. Khosla, J.M. Peterson, K. Egan and BL. Riggs (1994) Circulating levels of cytokines that modulate bone resorption: Effects of age and menopause in women. J. Bone Miner. Res. 9 1313-1318.
179. D. Metcalf and D.P. Gearing (1989) Fatal syndrome in mice engrafted with cells producing high levels of leukemia inhibitory factor. Proc. Natl. Acad. Sci. USA, 86 5948-5952.
180. M.E. Miranda-Carus, M. Benito-Miguel, A. Balsa, T. Cobo-Ibanez, C. Perez de Ayala, D. Pascual-Salcedo and E. Martin-Mola (2006) Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum. 54 1151-1164.
181. C. Miyaura, K. Kusano, T. Masuzawa, O. Chaki, Y. Onoe, M. Aoyagi, T. Sasaki, T. Tamura, Y. Koishihara, Y. Ohsugi and T. Suda (1995) Endogenous bone-resorbing factors in estrogen deficiency: Cooperative effects of IL-1 and IL-6. J. Bone Miner. Res. 10 1365-1373.
182. C. Miyaura, Y. Onoe, M. Inada, K. Maki, K. Ikuta, M. Ito and T. Suda (1997) Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc. Natl. Acad. Sci. USA, 94 9360-9365.
183. T. Miyazaki, H. Katagiri, Y. Kanegae, H. Takayanagi, Y. Sawada, A. Yamamoto, M.P. Pando, T. Asano, I.M. Verma, H. Oda, K. Nakamura and S. Tanaka (2000) Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J. Cell Biol. 148 333-342.
184. S.G. Mohamed, E. Sugiyama, K. Shinoda, H. Taki, H. Hounoki, H.O. Abdel-Aziz, M. Maruyama, M. Kobayashi, H. Ogawa and T. Miyahara (2007) Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone 41 592-602.
185. K.W. Moore, M.R. de Waal, R.L. Coffman and A. O'Garra (2001) Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 683-765.
186. M.L. Moreno, J.B. Crusius, A. Chernavsky, E. Sugai, A. Sambuelli, H. Vazquez, E. Maurino, A.S. Pena and J.C. Bai (2005) The IL-1 gene family and bone involvement in celiac disease. Immunogenetics 57 618-620.
187. B. Mosley, C.D. Imus C.De., D. Friend, N. Boian, B. Thoma, L.S. Park and D. Cosman (1996) Dual Oncostatin M (OSM) receptors. J. Biol. Chem. 271 32635-32643.
188. B.H. Mullin, R.L. Prince, I.M. Dick, F.M. Islam, D.J. Hart, T.D. Spector, A. Devine, F. Dudbridge and S.G. Wilson (2007) Bone structural effects of variation in the TNFRSF1B gene encoding the tumor necrosis factor receptor 2. Osteoporos. Int. 2008 Jul: 19(7): 961–8 Epub 2007 Nov
189. T. Mukai, F. Otsuka, H. Otani, M. Yamashita, K. Takasugi, K. Inagaki, M. Yamamura and H. Makino (2007) TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem. Biophys. Res. Commun. 356 1004-1010.
190. N. Nagata, H. Kitaura, N. Yoshida and K. Nakayama (2003) Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. Bone 33 721-732.
191. T. Naka, M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K. Yoshizaki, S. Akira and T. Kishimoto (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387 924-929.
192. Y. Nakano, K. Watanabe, I. Morimoto, Y. Okada, K. Ura, K. Sato, K. Kasono, T. Nakamura and S. Eto (1994) Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. J. Bone Miner. Res. 9 1533-1539.
193. A. Nakao, H. Fukushima, H. Kajiya, S. Ozeki and K. Okabe (2007) RANKL-stimulated TNFalpha production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways. Biochem. Biophys. Res. Commun. 357 945-950.
194. M.S. Nanes, W.M. McKoy and S.J. Marx (1989) Inhibitory effects of tumor necrosis factor-α and interferon-γ on deoxyribonucleic acid and collagen synthesis by rat osteosarcoma cells (ROS 17/2.8). Endocrinology 124 339-345.
195. H. Neubauer, A. Cumano, M. Muller, H. Wu, U. Huffstadt and K. Pfeffer (1998) Jak2 deficiency defines an essential developmental check-point in definitive hematopoiesis. Cell 93 397-409.
196. H. Neuhaus, B. Bettenhausen, P. Bilinski, D. Simon-Chazottes, J.-L. Guenet and A. Gossler (1994) Et12, a novel putative type-1 cytokine receptor expressed during mouse embryogenesis at high levels in skin and cells with skeletogenic potential. Dev. Biol. 166 531-542.
197. D.V. Novack and R. Faccio (2007) Jawing about TNF: New hope for cherubism. Cell 128 15-17.
198. C.A. O'Brien, I. Gubrij, S.C. Lin, R.L. Saylors and S.C. Manolagas (1999) STAT3 activation in stromal osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1, 25-dihydroxyvitamin D3 or parathyroid hormone. J. Biol. Chem. 274 19301-19308.
199. S. Ochi, M. Shinohara, K. Sato, H.J. Gober, T. Koga, T. Kodama, T. Takai, N. Miyasaka and H. Takayanagi (2007) Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc. Natl. Acad. Sci. USA, 104 11394-11399.
200. Y. Ogata, A. Kukita, T. Kukita, M. Komine, A. Miyahara, S. Miyazaki and O. Kohashi (1999) A novel role of IL-15 in the development of osteoclasts: Inability to replace its activity with IL-2. J. Immunol. 162 2754-2760.
201. J. Ohara and S.L. Perkins (1994) Interleukin 4 enhances osteoblast macrophage colony-stimulating factor, but not interleukin 6, production. Calcif. Tissue Int. 55 21-28.
202. Y. Okada, I. Morimoto, K. Ura, Y. Nakano, Y. Tanaka, S. Nishida, T. Nakamura and S. Eto (1998) Short-term treatment of recombinant murine interleukin-4 rapidly inhibits bone formation in normal and ovariectomized mice. Bone 22 361-365.
203. H. Okamura, H. Tsutsui, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, K. Akita, M. Namba, F. Tanabe, K. Konishi, S. Fukuda and M. Kurimoto (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378 88-91.
204. S. Onodera, J. Nishihira, K. Iwabuchi, Y. Koyama, K. Yoshida, S. Tanaka and A. Minami (2002) Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J. Biol. Chem. 277 7865-7874.
205. S. Onodera, S. Sasaki, S. Ohshima, N. Amizuka, M. Li, N. Udagawa, K. Irie, J. Nishihira, Y. Koyama, A. Shiraishi, H. Tohyama and K. Yasuda (2006) Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. J. Bone Miner. Res. 21 876-885.
206. S. Onodera, K. Suzuki, T. Matsuno, K. Kaneda, T. Kuriyama and J. Nishihira (1996) Identification of macrophage migration inhibitory factor in murine neonatal calvariae and osteoblasts. Immunology 89 430-435.
207. S. Onodera, K. Suzuki, K. Kaneda, M. Fujinaga and J. Nishihira (1999) Growth factor-induced expression of macrophage migration inhibitory factor in osteoblasts: relevance to the plasminogen activator system. Semin. Thromb. Hemost. 25 563-568.
208. Y. Onoe, C. Miyaura, T. Kaminakayashiki, Y. Nagai, K. Noguchi, Q.R. Chen, H. Seo, H. Ohta, S. Nozawa, I. Kudo and T. Suda (1996) IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J. Immunol. 156 758-764.
209. A. Orozco, E. Gemmell, M. Bickel and G.J. Seymour (2007) Interleukin 18 and periodontal disease. J. Dent. Res. 86 586-593.
210. S. Oshima, S. Onodera, N. Amizuka, M. Li, K. Irie, S. Watanabe, Y. Koyama, J. Nishihira, K. Yasuda and A. Minami (2006) Macrophage migration inhibitory factor-deficient mice are resistant to ovariectomy-induced bone loss. FEBS Lett. 580 1251-1256.
211. J. Owens and T.J. Chambers (1995) Differential regulation of osteoclast formation: interleukin 10 (cytokine synthesis inhibitory factor) suppresses formation of osteoclasts but not macrophages in murine bone marrow cultures. J. Bone Miner. Res. 10 S220.
212. J.M. Owens, A.C. Gallagher and T.J. Chambers (1996) IL-1O modulates formation of osteoclasts in murine hemopoietic cultures. J. Immunol. 157 936-940.
213. R. Pacifici, C. Brown, E. Puscheck, E. Friedrich, E. Slatopolsky, D. Maggio, R. McCracken and L.V. Avioli (1991) Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. USA, 88 5134-5138.
214. R. Pacifici, L. Rifas, R. McCracken, I. Vered, C. McMurtry, L.V. Avioli and W. Peck (1989) Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc. Natl. Acad. Sci. USA, 86 2398-2402.
215. R. Pacifici, L. Rifas, S. Teitelbaum, E. Slatopolski, R. McCracken, M. Bergfeld, W. Lee, L. Avioli and W. Peck (1987) Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc. Natl. Acad. Sci. USA, 84 4616-4620.
216. R. Pacifici, L. Vannice, L. Rifas and R.B. Kimble (1993) Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: Effects of menopause and estrogen/progesterone therapy. J. Clin. Endocrinol. Metab. 77 1135-1141.
217. P. Palmqvist, P. Lundberg, E. Persson, A. Johansson, I. Lundgren, A. Lie, H.H. Conaway and U.H. Lerner (2006) Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in STAT6-dependent pathway. J. Biol. Chem. 281 2414-2429.
218. E. Parganas, D. Wang, D. Stravopodis, D.J. Topham, J.-C. Marine, S. Teglund, E. Vanin, S. Bodner, O.R. Colamonici, J.M. van Deursen, G. Grosveld and J.N. Ihle (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93 385-395.
219. S.Y. Park, K. Saijo, T. Takahashi, M. Osawa, H. Arase, N. Hirayama, K. Miyake, H. Nakauchi, T. Shirasawa and T. Saitl (1995) Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3 771-782.
220. N.L. Paul and N.H. Ruddle (1988) Lymphotoxin. Annu. Rev. Immunol. 6 407-438.
221. R. Pearse, R. Feinman, K. Shuai, J.J. Darnell and J. Ravetch (1993) Interferon gamma-induced transcription of the high-affinity Fc receptor for IgG requires assembly of a complex that includes the 91-kDa subunit of transcription factor ISGF3. Proc. Natl. Acad. Sci. USA, 90 4314-4317.
222. G. Pelicci, L. Lanfrancone, F. Grignani, J. McGlade, F. Cavallo, G. Forni, I. Nicoletti, F. Grignani, T. Pawson and P. Pelicci (1992) A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70 93-104.
223. D. Pennica, K.L. King, K.J. Shaw, E. Luis, J. Rullamas, S.-M. Louh, W.C. Darbonne, D.S. Knutzon, R. Yen, K.R. Chien, J.B. Baker and W.I. Wood (1995) Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc. Natl. Acad. Sci. USA, 92 1142-1146.
224. D. Pennica, K.J. Shaw, T. Swanson, M.W. Moore, D.L. Shelton, K.A. Zioncheck, A. Rosenthal, T. Taga, N.F. Paoni and W.I. Wood (1995) Cardiotrophin-1 Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J. Biol. Chem. 270 10915-10922.
225. M. Peterlik, O. Hoffmann, P. Swetly, K. Klaushofer and K. Koller (1985) Recombinant gamma-interferon inhibits prostaglandin-mediated and parathyroid hormone-induced bone resorption in cultured neonatal mouse calvaria. FEBS Lett. 185 287-290.
226. J. Pfeilschifter, C. Chenu, A. Bird, G.R. Mundy and G.D. Roodman (1989) Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J. Bone Miner. Res. 4 113-118.
227. V.F.J. Quesniaux, P. Mayer, E. Liehl, K. Turner, SJ. Goldman and B. Fagg (1993) Review of a novel hematopoietic cytokine, Interleukin-11. Int. Rev. Exp. Pathol. 34A 205-214.
228. S.H. Ralston, L.-P. Ho, M.H. Helfrich, PS. Grabowski, P.W. Johnston and N. Benjamin (1995) Nitric oxide: A cytokine-induced regulator of bone resorption. J. Bone Miner. Res. 10 1040-1049.
229. P.D. Rathjen, S. Toth, A. Willis, J.K. Heath and A.G. Smith (1990) Differentiation inhibiting activity is produced in matrix-associated and diffusible forms that are generated by alternate promoter usage. Cell 62 1105-1114.
230. I. Reid, C. Lowe, J. Cornish, S. Skinner, D. Hilton, R. Willson, D. Gearing and T. Martin (1990) Leukemia inhibitory factor: A novel bone-active cytokine. Endocrinology 126 1416-1420.
231. J.A. Riancho, M.T. Zarrabeitia, J.M. Olmos, J.A. Amado and J. Gonzalez-Macias (1993) Effects of interleukin-4 on human osteoblast-like cells. Bone Miner. 21 53-61.
232. D. Rickard, G. Russell and M. Gowen (1992) Oestradiol inhibits the release of tumour necrosis factor but not interleukin 6 from adult human osteoblasts in vitro. Osteoporos. Int. 2 94-102.
233. S. Rodig, M.A. Meraz, J.M. White, P.A. Lampe, J.K. Riley, C.D. Arthur, K.L. King Jr., K.C.F. Sheehan, L. Yin, D. Pennica, E.M. Johnson Jr. and R.D. Schreiber (1998) Disruption of the Jak1 gene demonstrates obligatory and nonreduntant roles of the Jaks in cytokine-induced biologic responses. Cell 93 373-383.
234. G.D. Roodman (1992) Interleukin-6: An osteotropic factor. J. Bone Miner. Res. 7 475-478.
235. T.M. Rose and A.G. Bruce (1991) Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor and interleukin 6. Proc. Natl. Acad. Sci. USA, 88 8641-8645.
236. T.M. Rose, D. Weiford, N. Gunderson and A.G. Bruce (1994) Oncostatin M inhibits the differentiation of pluripotent embryonic stem cells. Cytokine 6 48-54.
237. J. Rothe, W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz and H. Bluethmann (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364 798-802.
238. L. Rothe, P. Collin-Osdoby, Y. Chen, T. Sunyer, L. Chaudhary, A. Tsay, S. Goldring, L. Avioli and P. Osdoby (1998) Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology 139 4353-4363.
239. S.M. Russell, A.D. Keegan, N. Harada, Y. Nakamura, M. Noguchi, P. Leland, M.C. Friedman, A. Miyajima, R.K. Puri, W.E. Paul and W.J. Leonard (1993) Interleukin-2 receptorγ chain: A functional component of the interleukin-4 receptor. Science 262 1880-1883.
240. M.R. Ryan, R. Shepherd, J.K. Leavey, Y. Gao, F. Grassi, F.J. Schnell, W.P. Qian, G.J. Kersh, M.N. Weitzmann and R. Pacifici (2005) An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc. Natl. Acad. Sci. USA, 102 16735-16740.
241. M. Sabatini, B. Boyce, T. Aufdemorte, L. Bonewald and G. Mundy (1988) Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc. Natl. Acad. Sci. USA, 85 5235.
242. H.B. Sadowski, K. Shuai, J.E.J. Darnell and M.Z. Gillman (1993) A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 261 1739-1744.
243. D.A. Sass, T. Liss, A.R. Bowman, B. Rucinski, S.N. Popoff, Z. Pan, Y.F. Ma and S. Epstein (1997) The role of the T-lymphocyte in estrogen deficiency osteopenia. J. Bone Miner. Res. 12 479-486.
244. K. Sato, A. Suematsu, K. Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, S. Tanaka, T. Kodama, S. Akira, Y. Iwakura, D.J. Cua and H. Takayanagi (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203 2673-2682.
245. N. Sato, N. Takahashi, K. Suda, M. Nakamura, M. Yamaki, T. Ninomiya, Y. Kobayashi, H. Takada, K. Shibata, M. Yamamoto, K. Takeda, S. Akira, T. Noguchi and N. Udagawa (2004) MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. J. Exp. Med. 200 601-611.
246. T. Sato, K. Watanabe, M. Masuhara, N. Hada and Y. Hakeda (2007) Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. J. Bone Miner. Metab. 25 19-27.
247. P. Seckinger, J. Klein-Nulend, C. Alander, R. Thompson, J.-M. Dayer and L. Raisz (1990) Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 bone resorption and prostaglandin production. J. Immunol. 145 4181.
248. K.C.F. Sheehan, J.K. Pinckard, C.D. Arthur, L.P. Dehner, D.V. Goeddel and R.D. Schreiber (1995) Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: Identification of a novel in vivo role for p75. J. Exp. Med. 181 607-617.
249. C. Shih, J.H. Lai and J.F. Shyu (2000) Activation of JAK/STAT signal transduction pathway by interleukin-11 in MC3T3-E1 osteoblastic cells. J. Bone Miner. Res. 15 S505. Abstract
250. H.H. Shin, J.E. Lee, E.A. Lee, B.S. Kwon and H.S. Choi (2006) Enhanced osteoclastogenesis in 4-1BB-deficient mice caused by reduced interleukin-10. J. Bone Miner. Res. 21 1907-1912.
251. A. Shioni, S.L. Teitelbaum, F.P. Ross, H.G. Welgus, H. Suzuki, J. Ohara and D.L. Lacey (1991) Interleukin 4 inhibits murine osteoclast formation in vitro. J. Cell. Biochem. 47 272-277.
252. K. Shuai, G. Stark, I. Kerr and J.J. Darnell (1993) A single phosphotyrosine residue of stat91 required for gene activation by interferon-γ. Science 261 1744-1746.
253. O. Silvennoninen, B. Wittuhn, F. Quelle, J. Cleveland, T. Yi and J. Ihle (1993) Structure of the murine JAK2 protein-tyrosine kinase and its role in IL-3 signal transduction. Proc. Natl. Acad. Sci. USA, 90 8429-8433.
254. J.E. Sims, M.A. Gayle, J.L. Slack, M.R. Alderson, TA. Bird, J.G. Giri, F. Colotta, F. Re, A. Mantovani, K. Shanebeck, K.H. Grabstein and S.K. Dower (1993) Interleukin 1 signaling occurs exclusively via the type I receptor. Proc. Natl. Acad. Sci. USA, 90 6155-6159.
255. N.A. Sims, B.J. Jenkins, A. Nakamura, J.M.W. Quinn, R. Li, M.T. Gillespie, M. Ernst, L. Robb and T.J. Martin (2005) Interleukin-11 receptor signaling is required for normal bone remodeling. J. Bone Miner. Res. 20 1093-1102.
256. N.A. Sims, E.C. Walker, I.J. Poulton, N.E. McGregor, M.E. Gillespie and T.J. Martin (2007) Oncostatin M is an essential stimulus of bone formation and osteoclastogenesis. J. Bone Miner. Res. 1068, S19 Abstract
257. D.D. Smith, M. Gowen and G.R. Mundy (1987) Effects of interferongamma and other cytokines on collagen synthesis in fetal rat bone cultures. Endocrinology 120 2494-2499.
258. H.Y. Song, E.S. Jeon, Kim, J.S. Jung and J.H. Kim (2007) Oncostatin M promotes osteogenesis and suppresses adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells. J. Cell Biochem. 101 1238-1251.
259. P. Soriano, C. Montgomery, R. Geske and A. Bradley (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64 693-702.
260. S. Srivastava, M.N. Weitzmann, S. Cenci, F.P. Ross, S. Adler and R. Pacifici (1999) Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J. Clin. Invest. 104 503-513.
261. N. Stahl (1994) Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL6β receptor components. Science 263 92.
262. N. Stahl, T.J. Farruggella, T.G. Boulton, Z. Zhong, J.E. Darnell Jr. and G.D. Yancopoulos (1995) Choice of Stats and other substrates specified by molecular tyrosine-based motifs in cytokine receptors. Science 267 1349-1353.
263. R. Starr, T.A. Willson, E.M. Viney, L.J. Murry, J.R. Rayner, B.J. Jenkins, T.J. Gonda, W.S. Alexander, D. Metcalf, N.A. Nicola and D.J. Hamilton (1997) A family of cytokine inducible inhibitors of signaling. Nature 387 917-921.
264. P. Stashenko, F.E. Dewhirst, W.J. Peros, R.L. Kent and J.M. Ago (1987) Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J. Immunol. 138 1464-1468.
265. J.L. Stock, J.A. Coderre, B. McDonald and L.J. Rosenwasser (1989) Effects of estrogen in vivo and in vitro on spontaneous interleukin-1 release by monocytes from postmenopausal women. J. Clin. Endocrinol. Metab. 68 364-368.
266. P.M. Stuart, A. Zlotnik and J.G. Woodward (1988) Induction of class I and class II MHC antigen expression on murine bone marrow-derived macrophages by IL-4. J. Immunol. 140 1542-1547.
267. T. Sunyer, L. Rothe, X.S. Jiang, P. Osdoby and P. Collin-Osdoby (1996) Proinflammatory agents, IL-8 and IL-10, upregulate inducible nitric oxide synthase expression and nitric oxide production in avian osteoclast-like cells. J. Cell. Biochem. 60 469-483.
268. N. Takahashi, G.R. Mundy and G.D. Roodman (1986) Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells. J. Immunol. 137 3544-3549.
269. H. Takayanagi, K. Ogasawara, S. Hida, T. Chiba, S. Murata, K. Sato, A. Takaoka, T. Yokochi, H. Oda, K. Tanaka, K. Nakamura and T. Taniguchi (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408 600-605.
270. H. Takayanagi (2005) Inflammatory bone destruction and osteoimmunology. J. Periodontal Res. 40 287-293.
271. H. Takayanagi, S. Kim, K. Matsuo, H. Suzuki, T. Suzuki, K. Sato, T. Yokochi, H. Oda, K. Nakamura, N. Ida, E.F. Wagner and T. Taniguchi (2002) RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416 744-749.
272. K. Takeda, K. Noguchi, W. Shi, T. Tanaka, M. Matsumoto, N. Yoshida, T. Kishimoto and S. Akira (1997) Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA, 94 3801-3804.
273. K. Takeda, T. Kaisho, N. Yoshida, J. Takeda, T. Kishimoto and S. Akira (1998) Stat3 activation is responsible for IL-6 dependent T-cell proliferation through preventing apoptosis: Generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 161 4652-4660.
274. A. Takeshita, S. Hanazawa, S. Amano, T. Matumoto and S. Kitano (1993) IL-1 induces expression of monocyte chemoattractant JE in clonal mouse osteoblastic cell line MC3T3-E1. J. Immunol. 150 1554-1562.
275. Y. Takeuchi, S. Watanabe, G. Ishii, S. Takeda, K. Nakayama, S. Fukumoto, Y. Kaneta, D. Inoue, T. Mataumoto, K. Harigaya and T. Fujita (2002) Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J. Biol. Chem. 277 49011-49018.
276. T. Tamura, N. Udagwa, N. Takahashi, C. Miyaura, S. Tanaka, T. Kisimoto and T. Suda (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA, 90 11924-11928.
277. N. Tanabe, M. Maeno, N. Suzuki, K. Fujisaki, H. Tanaka, B. Ogiso and K. Ito (2005) IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. Life Sci. 77 615-626.
278. L.A. Tartaglia, D. Pennica and D.V. Goeddel (1993) Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J. Biol. Chem. 268 18542-18548.
279. A.H.J. Tashjian, E.F. Voelkel, M. Lazzaro, D. Goad, T. Bosma and L. Levine (1987) Tumor necrosis factor-α (Cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology 120 2029-2036.
280. P.N. Tasker, O.M. Albagha, C.B. Masson, D.M. Reid and S.H. Ralston (2004) Association between TNFRSF1B polymorphisms and bone mineral density, bone loss and fracture. Osteoporos. Int. 15 903-908.
281. D.C. Thomis, C.B. Gurniak, E. Tivol, A.H. Sharpe and L.J. Berg (1995) Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270 794-797.
282. B.M. Thomson, G.R. Mundy and T.J. Chambers (1987) Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J. Immunol. 138 775-779.
283. G. Toraldo, C. Roggia, W.P. Qian, R. Pacifici and M.N. Weitzmann (2003) IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl. Acad. Sci. USA, 100 125-130.
284. N. Udagawa, N. Takahashi, T. Katagiri, T. Tamura, S. Wada, D.M. Findlay, T.J. Martin, H. Hirota, T. Taga, T. Kishimoto and T. Suda (1995) Interleukin-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J. Exp. Med. 182 1461-1468.
285. Y. Ueki, C.Y. Lin, M. Senoo, T. Ebihara, N. Agata, M. Onji, Y. Sheki, T. Kawai, P.M. Mukherjee, E. Reichenberger and B.R. Olsen (2007) Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 “cherubism” mice. Cell 128 71-83.
286. K. Ueno, T. Katayama, T. Miyamoto and Y. Koshihara (1992) Interleukin-4 enhances in vitro mineralization in human osteoblast-like cells. Biochem. Biophys. Res. Commun. 189 1521-1526.
287. E. Van Beek, L. Van der Wee-Pals, M. van de Ruit, P. Nijweide, S. Papapoulos and C. Lowik (1993) Leukemia inhibitory factor inhibits osteoclastic resorption, growth, mineralization, and alkaline phosphatase activity in fetal mouse metacarpal bones in culture. J. Bone Miner. Res. 8 191-198.
288. R.L. Van bezooijen, H.C. Farih-Sips, S.E. Papapoulos and C.W. Lowik (1999) Interleukin-17: A new bone acting cytokine in vitro. J. Bone Miner. Res. 14 1513-1521.
289. P. Van Vlasselaer, B. Borremans, R. Van Der Heuvel, U. Van Gorp and R. de Waal Malefyt (1993) Interleukin-10 inhibits the osteogenic activity of mouse bone marrow. Blood 82 2361-2370.
290. R.J. Van't Hof, K.J. Armour, L.M. Smith, K.E. Armour, X.Q. Wei, F.Y. Liew and S.H. Ralston (2000) Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. Proc. Natl. Acad. Sci. USA, 97 7993-7998.
291. R.J. Van't Hof and S.H. Ralston (1997) Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J. Bone Miner. Res. 12 1797-1804.
292. P. Vandenabeele, W. Declercq, B. Vanhaesebroeck, J. Grooten and W. Fiers (1995) Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J. Immunol. 154 2904-2913.
293. S.J. Vargas, A. Naprta, M. Glaccum, S.K. Lee, J. Kalinowski and J.A. Lorenzo (1996) Interleukin-6 expression and histomorphometry of bones from mice deficient for receptors for interleukin-1 or tumor necrosis factor. J. Bone Miner. Res. 11 1736-1744.
294. O.N. Vidal, K. Sjögren, B.I. Eriksson, Ö. Ljunggren and C. Ohlsson (1998) Osteoprotegerin mRNA is increased by interleukin-lα in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem. Biophys. Res. Commun. 248 696-700.
295. A. Vignery, T. Niven-Fairchild and M.H. Shepard (1990) Recombinant murine interferon-gamma inhibits the fusion of mouse alveolar macrophages in vitro but stimulates the formation of osteoclast-like cells on implanted syngenic bone particles in mice in vivo. J. Bone Miner. Res. 5 637-644.
296. J. Wang and K. Walsh (1996) Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273 359-361.
297. C.B. Ware, M.C. Horowitz, B.R. Renshaw, J.S. Hunt, D. Liggitt, S. Koblar, B.C. Gliniak, H.J. McKenna, JJ. Peshon, G. Stamatoy-annopoulos, B. Thomas, P. Donovan, P. Bartless, C.R. Willis, B.D. Wright, M.K. Capenter, B.L. Davison and D.P. Gearing (1995) Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene results in placental, skeletal and neural defects that result in perinatal death. Development 121 1283-1299.
298. K. Watanabe, Y. Tanaka, I. Morimoto and S. Eto (1990) Interleukin 4 as a potent inhibitor of bone resorption. Biochem. Biophys. Res. Commun. 172 1035-1041.
299. C.T. Weaver, R.D. Hatton, P.R. Mangan and L.E. Harrington (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25 821-852.
300. S. Wei, H. Kitaura, P. Zhou, F.P. Ross and S.L. Teitelbaum (2005) IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115 282-290.
301. W.Y. Weiser, P.A. Temple, J.S. Witek-Giannotti, H.G. Remold, S.C. Clark and J.R. David (1989) Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. USA, 86 7522-7526.
302. M.N. Weitzmann, S. Cenci, L. Rifas, C. Brown and R. Pacifici (2000) Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines (In Process Citation). Blood 96 1873-1878.
303. M.N. Weitzmann, C. Roggia, G. Toraldo, L. Weitzmann and R. Pacifici (2002) Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J. Clin. Invest. 110 1643-1650.
304. A.F. Wilks, A.G. Harpur, R.R. Kurban, S.J. Ralph, G. Zu;aurcher and A. Ziemiecki (1991) Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol. 11 2057-2065.
305. S.R. Williams, Y. Jiang, D. Cochran, G. Dorsam and DT. Graves (1992) Regulated expression of monocyte chemoattractant protein-1 in normal human osteoblastic cells. Am. J. Physiol. 263 C194-cC199.
306. B.A. Witthuhn, O. Silvennoinen, O. Miura, K.S. Lai, C. Cwik, E.T. Liu and J.N. Ihle (1994) Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370 153-157.
307. B.R. Wong, D. Besser, N. Kim, J.R. Arron, M. Vologodskaia, H. Hanafusa and Y. Choi (1999) TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell. 4 1041-1049.
308. L.X. Xu, T. Kukita, A. Kukita, T. Otsuka, Y. Niho and T. Iijima (1995) Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system. J. Cell. Physiol. 165 624-629.
309. N. Yamada, S. Niwa, T. Tsujimura, T. Iwasaki, A. Sugihara, H. Futani, S. Hayashi, H. Okamura, H. Akedo and N. Terada (2002) Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone 30 901-908.
310. M. Yamamura, M. Kawashima, M. Taniai, H. Yamauchi, T. Tanimoto, M. Kurimoto, Y. Morita, Y. Ohmoto and H. Makino (2001) Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 44 275-285.
311. G.Q. Yao, B.H. Sun, K.L. Insogna and E.C. Weir (2000) Nuclear factor-kappaB p50 is required for tumor necrosis factor-α-induced colony-stimulating factor-1 gene expression in osteoblasts. Endocrinology 141 2914-2922.
312. Z. Yao, P. Li, Q. Zhang, E.M. Schwarz, P. Keng, A. Arbini, B.F. Boyce and L. Xing (2006) Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J. Biol. Chem. 281 11846-11855.
313. H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S-I. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi and T. Suda (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA, 95 3597-3602.
314. T. Yoneda, M.A. Alsina, J.B. Chavez, L. Bonewald, R. Nishimura and G.R. Mundy (1991) Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. J. Clin. Invest. 87 977-985.
315. H. Yoshida, S. Hayashi, T. Kunisada, M. Ogawa, S. Nishikawa, H. Okamura, T. Sudo, L.D. Shultz and S. Nishikawa (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345 442-444.
316. A. Yoshimura, T. Ohkubo, T. Kiguchi, N.A. Jenkins, D.J. Gilbert, N.G. Copeland, T. Hara and A. Miyajima (1995) A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin-3 and erythropoietin receptors. EMBO J. 14 2816-2826.
317. J.M. Zarling, M. Shoyab and H. Marquardt (1986) Oncostatin M: A growth regulator produced by differentiated histiocytic lymphoma cells. Proc. Natl. Acad. Sci. USA, 83 9739-9743.
318. Q. Zhang, I.R. Badell, E.M. Schwarz, K.E. Boulukos, Z. Yao, B.F. Boyce and L. Xing (2005) Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum. 52 2708-2718.
319. Y.H. Zhang, A. Huelsmann, M.M. Tondravi, A. Mukherjee and Y. Abu-Amer (2000) Tumor necrosis factor-alpha stimulates RANKL-induced osteoclastogenesis via coupling of TNFrl and RANK signaling pathways. J. Biol. Chem. 276 563-568.
320. J.-F. Zhu, A.J. Valente, J.A. Lorenzo, D. Carnes and D.T. Graves (1994) Expression of monocyte chemoattractant protein 1 in human osteoblastic cells stimulated by proinflammatory mediators. J. Bone Miner. Res. 9 1123-1130.
321. W. Zou, A. Amcheslavsky, S. Takeshita, H. Drissi and Z. Bar-Shavit (2005) TNF-alpha expression is transcriptionally regulated by RANK ligand. J. Cel. Physiol. 202 371-378.
322. J. Zwerina, K. Redlich, K. Polzer, L. Joosten, g. Kronke, J. Distler, A. Hess, N. Pundt, T. Pap, O. Hoffmann, J. Gasser, C. Scheinecker, J.S. Smolen, W. van den Berg and G. Schett (2007) TNF-induced structural joint damage is mediated by IL-1. Proc. Natl. Acad. Sci. USA 104 11742-11747.